Make Better Decisions

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Julphar
Colorcon
Express Scripts
Deloitte
Cerilliant
Cipla
US Department of Justice
UBS
Merck

Generated: January 18, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,645,961

« Back to Dashboard

Which drugs does patent 6,645,961 protect, and when does it expire?

Patent 6,645,961 protects CRIXIVAN and is included in one NDA.
Summary for Patent: 6,645,961
Title: Dry granulation formulation for an HIV protease inhibitor
Abstract:This invention relates to a dry granulation capsule formulation of the HIV protease inhibitor, indinavir sulfate, which is useful in the treatment of AIDS, ARC or HIV infection. Processes for making the oral formulation are also disclosed.
Inventor(s): Lui; Chung Y. (Lansdale, PA), Ostovic; Drazen (Lansdale, PA), Katdare; Ashok V. (Norristown, PA), Stelmach; Christine (Tinton Falls, NJ)
Assignee: Merck & Co., Inc. (Rahway, NJ)
Application Number:09/045,885
Patent Claim Types:
see list of patent claims
Composition; Dosage form; Formulation; Process;

Drugs Protected by US Patent 6,645,961

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Merck Sharp Dohme CRIXIVAN indinavir sulfate CAPSULE;ORAL 020685-006 Apr 19, 2000 DISCN No No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Merck Sharp Dohme CRIXIVAN indinavir sulfate CAPSULE;ORAL 020685-003 Mar 13, 1996 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Merck Sharp Dohme CRIXIVAN indinavir sulfate CAPSULE;ORAL 020685-005 Dec 17, 1998 DISCN No No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Merck Sharp Dohme CRIXIVAN indinavir sulfate CAPSULE;ORAL 020685-001 Mar 13, 1996 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Novartis
Federal Trade Commission
US Department of Justice
Moodys
Fish and Richardson
Farmers Insurance
McKesson
Dow
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot